• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

Abortion pill mifepristone sparks new pro-life debate as some doctors stress safety concerns

by February 4, 2025
written by February 4, 2025

Pro-choice lawmakers, doctors and advocates have argued the science is settled when it comes to the controversial abortion pill mifepristone. They say the drug is safe and needs to be widely available with virtually no restrictions. Even some GOP lawmakers have shown support for retaining women’s access to the pill, which is much more widely available today than it was just a few years ago. 

President Donald Trump, meanwhile, has yet to stake out a formal position on how he will approach the controversial abortion pill. Although he took several measures in his first few days in office to prevent taxpayer dollars from funding or promoting abortion, he has yet to respond to pro-life demands to reinstate specific restrictions on mifepristone.

‘The potentially tragic results of these drugs have been illustrated by the recently reported deaths of Amber Thurman and Candi Miller,’ Dr. Christina Francis, CEO of the American Association of Pro-Life OBGYNs, told Fox News Digital. ‘Denying the risks of mifepristone will only ensure that more women like Amber and Candi are left to undergo painful and potentially dangerous drug-induced abortions without the bare minimum quality of medical care.’

While pro-choice advocates have suggested the deaths of Thurman and Miller were the result of anti-abortion laws and the chilling effect they have incurred on women seeking abortions, Francis said their deaths were instead the result of a powerful medication that lacks the necessary safeguards. 

‘Many of the studies that abortion advocates like to quote to state that mifepristone has very few complications don’t actually reflect real world use of mifepristone,’ she said. ‘Most of those studies, women will have had an in-person visit, as well as an ultrasound, actually documenting how far along they are in their pregnancy, as well as ensuring that they did not have an ectopic pregnancy before they receive those drugs. When, in fact, that’s not real-world use right now.’

Francis pointed out that real-world use actually ‘means that they order them online.’

 

When mifepristone was first approved in 2000 by the Food And Drug Administration (FDA), numerous safeguards were put in place. Those included requirements that the medication be dispensed in-person and that patients receive appropriate follow-up care. It also limited the gestational time frame during which pregnant women could use the pill to seven weeks. However, over time, those restrictions were loosened more and more. By 2021, women could get mifepristone without in-person visits, and it was left up to the doctor to trust the patient’s account of how far along her pregnancy was.

‘They’re not seen by any kind of medical professional to confirm their gestational age or to rule out an ectopic pregnancy, which we know happens in one in 50 pregnancies,’ Francis said. ‘If you look at the FDA’s own label – and again, this was when there was still the in-person dispensing requirement – their own label says that one in 25 women will go to the emergency room due to complications related to these drugs. That is not a safe drug. Safe drugs don’t send one in 25 people to the emergency room.’

‘The only way to tell the bleeding, cramping, and pain is from a miscarriage, the abortion pill, or even from an ectopic pregnancy, is to actually do an ultrasound,’ Dr. William Lile, a pro-life OB-GYN who has delivered more than 5,000 babies, told Fox News Digital.   

The removal of in-person visits is a major aspect of the more lax restrictions that people like Francis and Lile want to see reversed. A big reason for that is due to the similarity of the side effects exhibited by both mifepristone usage and life-threatening ectopic pregnancies, which have increased due to the growing prevalence of Intrauterane Devices (IUDs) and sexually transmitted diseases like chlamydia and gonorrhea, Francis wrote in an op-ed for the Wall Street Journal.

‘If she has an ectopic pregnancy that’s undiagnosed, she starts having these symptoms. She’s going to think that it’s the result of the abortion drugs that she took, and it’s normal, and she’s going to stay home while she’s bleeding into her abdomen and losing precious time. That could be the difference between life and death,’ Francis said. 

Mifepristone is also prone to causing retained tissue and atypical sepsis as well, something Thurman suffered from before her death.

‘When we know that this drug carries these kinds of complications, we are saying women deserve better care and better oversight when they’re being given these drugs,’ Francis said. ‘These are not benign drugs. Women deserve follow-up care. They deserve ongoing care.’

Pro-choice advocates argue that mifepristone is safe, citing numerous studies showing its safety and effectiveness, including for treating miscarriages, from as far back as 1988. The U.S. Department of Health and Human Services, the American Medical Association and the American College of Obstetricians and Gynecologists call the drug safe and effective for abortion and miscarriage care. 

Autumn Katz, interim director of litigation at the Center for Reproductive Rights, called claims against mifepristone ‘false,’ noting they have been ‘thoroughly debunked.’ 

‘It has been used in combination with misoprostol by over 5.9 million patients in the U.S.,’ she said. ‘Numerous studies have repeatedly proven its safety and effectiveness for ending an early pregnancy, and mifepristone is also frequently used as a safe and effective treatment for early miscarriage.’

Fox News Digital spoke to a pro-life emergency room doctor who said he uses mifepristone in conjunction with other drugs to remedy miscarriages. However, according to Lile and Francis, mifepristone’s assistance is not statistically significant, or necessary when treating miscarriages. Neither does it remove the need for in-person visits, they said. 

‘When people think of it outside of the abortion context, they understand how important that in-person evaluation is, how important it is to know exactly how far along someone is,’ Francis said. ‘So that’s what we’re calling for, and [in-person evaluations] being put back into place would not impact a physician’s ability to use that drug to treat miscarriage, if that is their protocol for treating miscarriage.’ 

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
White House expecting ‘spike’ in federal resignations as at least 20K take buyouts
next post
Trump moves to develop sovereign wealth fund to ‘create value for American citizens’

related articles

Hunter Biden seen driving Toyota rental in South...

May 31, 2025

Trump tariff plan faces uncertain future as court...

May 31, 2025

Musk confident DOGE will save $1 trillion as...

May 30, 2025

Who will be Elon’s successor? The top names...

May 30, 2025

Elon Musk sports black eye at farewell presser...

May 30, 2025

Biden says he could ‘beat the hell out...

May 30, 2025

Donald Trump fires National Portrait Gallery director for...

May 30, 2025

‘American hero’ or ‘failure’: Elon Musk’s DOGE departure...

May 30, 2025

Unfinished Business: The budget cuts Musk couldn’t complete...

May 30, 2025

Alleged attempt to impersonate White House chief of...

May 30, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Josh Shapiro, Tim Walz: Most Americans have never heard of possible Harris VP picks

    August 6, 2024
  • US, Russian officials propose peace plan, lay ‘groundwork for cooperation’ in Riyadh

    February 18, 2025
  • Hidin’ Harris 2024 is a terrible strategy and a danger for our democracy

    August 27, 2024
  • Long ESTC:  Elastic’s Robust Earnings and AI Initiatives Propel Bullish Stock Momentum

    March 3, 2025
  • Ethereum inconclusive over the weekend drops to a new low

    August 12, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,735)
  • Investing (624)
  • Stock (775)

Latest Posts

  • Why ON Semiconductor is a strong buy despite recent market challenges

    November 7, 2024
  • Republicans weigh in on what they hope and expect to hear in Trump’s RNC speech: ‘This is his moment’

    July 18, 2024
  • Emmanuel Macron calls ’emergency meeting’ for European leaders to discuss Trump: report

    February 16, 2025

Recent Posts

  • Trump Cabinet official vows major food stamp reforms that will help hungry children

    April 29, 2025
  • Dem claims Trump wielding nuclear strike authority ‘should terrify you’ — then people point out the obvious

    December 13, 2024
  • Left-wing movie director Oliver Stone rips Democrats’ ‘lying’ Russiagate probe against Trump

    April 6, 2025

Editor’s Pick

  • Millions spent by Biden on COVID ‘vaccine hesitancy’ campaign slashed by Trump NIH: report

    March 14, 2025
  • US Ambassador to Ukraine Bridget Brink to step down amid high-stakes war diplomacy

    April 11, 2025
  • GGP Share Price Continues Decline. Will It Recover Soon?

    August 7, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock